Assistant Professor of Pathology Member-Michigan Center for Translational Pathology MLabs Genitourinary Service Line Director Co-Director, University of Michigan Rapid Autopsy Discovery Progr
Biography
Dr. Rohit Mehra is an Assistant Professor in Department of Pathology at the University of Michigan and a faculty member at Michigan Center for Translational Pathology (MCTP). In addition to routine clinical and diagnostic responsibilities, Dr. Mehra serves as MLabs' Genitourinary (GU) Service Line Director and is also Co-Director of University of Michigan Rapid Autopsy Discovery Program. Dr. Mehra completed his residency in anatomic pathology at the University of Michigan in 2011 after first serving for five years as a research investigator in the laboratory of Dr. Arul Chinnaiyan, Director of MCTP. Dr. Mehra completed fellowship training in GU pathology at Memorial Sloan Kettering Cancer Center under the Direction of Dr. Victor Reuter.
Working with colleagues at MCTP, Dr. Mehra played an important role in discovery of recurrent fusion of TMPRSS2 and ETS transcription factor genes, now recognized as an important driver mutation in prostate carcinomas. He has continued to focus on the mutational landscape of malignant GU neoplasms as well as biomarkers important for diagnosis and management of affected patients. Over the last decade he has served as the author of more than 100 publications in the peer-reviewed literature, several book chapters, and abstracts. Dr. Mehra has been invited on numerous occasions to deliver extramural, national and international presentations. To facilitate clinical translation of emerging molecular advances in GU malignancies, Dr. Mehra has helped launch novel, clinically significant molecular oncology results into assays for diagnostic, prognostic, and/or therapeutic use.
Working with colleagues at MCTP, Dr. Mehra played an important role in discovery of recurrent fusion of TMPRSS2 and ETS transcription factor genes, now recognized as an important driver mutation in prostate carcinomas. He has continued to focus on the mutational landscape of malignant GU neoplasms as well as biomarkers important for diagnosis and management of affected patients. Over the last decade he has served as the author of more than 100 publications in the peer-reviewed literature, several book chapters, and abstracts. Dr. Mehra has been invited on numerous occasions to deliver extramural, national and international presentations. To facilitate clinical translation of emerging molecular advances in GU malignancies, Dr. Mehra has helped launch novel, clinically significant molecular oncology results into assays for diagnostic, prognostic, and/or therapeutic use.
